Clinical Trials · NCT03541447
Tolvaptan-Octreotide LAR Combination in ADPKD
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Enrollment
- 20
- Start date
- Dec 2018
- Locations
- 1 site, Italy
- Primary endpoint
- Glomerular Filtration Rate (GFR)